Leslie Popplewell
YOU?
Author Swipe
View article: Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial Open
Despite advances in targeted and cellular therapies, outcomes for patients with Richter’s transformation (RT) and transformed non-Hodgkin lymphoma (tNHL) remain dismal. In this study we report safety and efficacy of the combination of the …
View article: 135 | LONG‐TERM FOLLOW UP OF THE VALOR (VENETOCLAX, LENALIDOMIDE, RITUXIMAB) IN PATIENTS W/ UNTREATED MANTLE CELL LYMPHOMA
135 | LONG‐TERM FOLLOW UP OF THE VALOR (VENETOCLAX, LENALIDOMIDE, RITUXIMAB) IN PATIENTS W/ UNTREATED MANTLE CELL LYMPHOMA Open
View article: 138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) Open
View article: Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry Open
Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2 lines of therapy. When used in…
View article: Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy
Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy Open
Purpose/objective(s) Bridging radiation therapy (bRT) is increasingly being utilized prior to chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). It is unknown how the extent of cytoreduction during bRT impacts…
View article: Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma Open
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for available salvage therapies have limited options for long-term disease control, necessitating novel treatments. Previously, magrolimab (anti–clust…
View article: Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial Open
Relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) is generally considered incurable with current treatment options. Previous phase 1b/2 results showed combining magrolimab (anti–cluster-of-differentiation [CD] 47 antibody) wit…
View article: Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma Open
Patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL) from indolent B-cell lymphomas, including Richter transformation (RT), have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and comp…
View article: Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update Open
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial reported high response rates…
View article: Prognostic Significance of Positron Emission Tomography Delta Radiomics Following Bridging Therapy in Patients with Large B-Cell Lymphoma Undergoing CAR T-Cell Therapy
Prognostic Significance of Positron Emission Tomography Delta Radiomics Following Bridging Therapy in Patients with Large B-Cell Lymphoma Undergoing CAR T-Cell Therapy Open
View article: Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma Open
Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard‐of‐care CAR T‐cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preserve efficacy, improve safety, and addres…
View article: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Open
View article: P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL) Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Despite recent progress in treating LBCL, approximately 50% to 60% of pts will either not achieve a complete response (CR) or will relapse with current first- or second-line…
View article: S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA Open
Background: Axicabtagene ciloleucel (axi-cel) is an autologous chimeric antigen receptor (CAR) T-cell therapy approved for adult patients with relapsed or refractory (R/R) follicular lymphoma after ≥2 lines of systemic therapy. In the prim…
View article: “Democratizing” cancer care: City of Hope’s national enterprise model for delivering cancer care.
“Democratizing” cancer care: City of Hope’s national enterprise model for delivering cancer care. Open
103 Background: Despite progress in cancer care, many patients do not have access to innovative care including participation in clinical trials. In 2021, City of Hope (COH), as part of a national expansion of its established cancer service…
View article: Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma Open
Outcomes after programmed death-1 (PD-1) blockade in B-cell lymphomas are disappointing with few durable responses. Histone deacetylase inhibitors exhibit favorable immunomodulatory effects and demonstrate synergistic anti-tumor immune res…
View article: Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade Open
This phase 1 study evaluated the addition of vorinostat to pembrolizumab in patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma, and follicular lymphoma. We report the results in cases of …
View article: Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Open
Background: Axicabtagene ciloleucel (axi-cel) is an autologous CAR T-cell therapy approved for adult patients (pts) with R/R FL after ≥2 lines of systemic therapy. In the primary analysis of the pivotal ZUMA-5 trial, 94% of pts who receive…
View article: DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (<i>R</i>/<i>R</i> LBCL)
DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (<i>R</i>/<i>R</i> LBCL) Open
Introduction: Despite progress in treating LBCL, approximately 50% to 60% of pts will either not achieve a complete response (CR) or will relapse after current first- or second-line therapy. Autologous anti-CD19 chimeric antigen receptor (…
View article: A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)
A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL) Open
Signal regulatory protein alpha (SIRPα) is the receptor for cluster of differentiation (CD)47, a potent “don't eat me” signal for macrophages. Disruption of CD47‐SIRPα signaling in the presence of prophagocytic signals can lead to enhanced…
View article: Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered with CD19-targeted chimeric antigen …
View article: Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered with CD19-targeted chimeric antigen …
View article: Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who are untreated. Over the last s…
View article: Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Supplementary Figures and Legends
View article: Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Supplementary Figures and Legends
View article: Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy Open
Background: The purpose of this study was to examine the association between baseline skeletal muscle measurements, acute toxicity (immune effector cell–associated neurotoxicity syndrome [ICANS], cytokine release syndrome), and treatment e…
View article: Data from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas
Data from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas Open
Purpose:In this phase I study (NCT01307267), we evaluated safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular lymphoma (FL) and other…
View article: Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma Open
Supplementary Figure 6
View article: Supplementary Figure S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas
Supplementary Figure S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas Open
(A) Levels of soluble 4-1BB/CD137 and (B) changes in CD8+ T cells from Cycle 1 day 1, in individual patients by dose group.
View article: Supplementary Figure 2 from Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Supplementary Figure 2 from Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma Open
Supplementary Figure 2